---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-270884"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:05:31.519831+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Madrigal Q3 operating expenses $98.5M; FDA Priority Review for resmetirom; $500M October financing

## Summary
- FDA accepted NDA for resmetirom, granted Priority Review; PDUFA date March 14, 2024; no advisory committee planned.
- Bill Sibold appointed CEO in Sep 2023; previously EVP at Sanofi, led Dupixent launch.
- $500M public offering closed Oct 2023; net proceeds $472M for pre-launch activities.
- Cash and securities $232.4M as of Sep 30, 2023, prior to October offering.
- Q3 2023 operating expenses $98.5M ($71.0M R&D, $27.6M G&A); nine-month total $263.3M.

## SEC filing metadata
- accession: 0001193125-23-270884
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312523270884/0001193125-23-270884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312523270884/d583670d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-270884
- JSON: https://secwatch.observer/filing/0001193125-23-270884.json
- Plain text: https://secwatch.observer/filing/0001193125-23-270884.txt

## Key facts
- Earnings Releases
  MADRIGAL PHARMACEUTICALS, INC. reported financial results for third quarter 2023.
  - Period: third quarter 2023
  - Result: reported results
  source text: On November 6, 2023, Madrigal Pharmaceuticals, Inc. (the "Company") issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312523270884/0001193125-23-270884-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.